Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XmAb 662

Next Previous
Drug Profile

XmAb 662

Alternative Names: IL-12 heterodimeric Fc-fusion - Xencor; IL12 Fc - Xencor; Interleukin 12 heterodimeric Fc-fusion therapeutic - Xencor; XmAb-662

Latest Information Update: 06 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD8 positive T lymphocyte stimulants; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 May 2024 Xencor terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) due to business reasons(NCT05996445)
  • 31 Jul 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05996445)
  • 09 Jan 2023 Xencor plans a phase I trial for Solid tumours (Late-stage disease) in mid-2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top